The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox).

ATP binding cassette (ABC) drug transporters play an important role in cancer drug resistance, protection against xenobiotics, and in general in the passage of drugs through cellular and tissue barriers. This review explores how human ABC transporters modulate the pharmacological effects of various drugs, and how this predictable ADME-TOX modulation can be used during the process of drug discovery and development. We provide a description of the relevant human ABC drug transporters and review the models and assay systems that can be applied for the analysis of their expected drug interactions. The use of the in vitro, in vivo, in silico models, their combination, and the emerging clinical information are evaluated with respect to their potential application in early drug screening.

[1]  D. Greenblatt,et al.  Saint John's wort: An in vitro analysis of P‐glycoprotein induction due to extended exposure , 2001, British journal of pharmacology.

[2]  R. Kim,et al.  Pharmacogenomics of the OATP and OAT families. , 2004, Pharmacogenomics.

[3]  Clifford A Goudey,et al.  Aquaculture in Offshore Zones , 2006, Science.

[4]  M. Varma,et al.  Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery. , 2006, Current opinion in chemical biology.

[5]  H. Nakauchi,et al.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.

[6]  I. Pastan,et al.  Fluorescent cellular indicators are extruded by the multidrug resistance protein. , 1993, The Journal of biological chemistry.

[7]  G. Szakács,et al.  Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. , 2006, Physiological reviews.

[8]  Jos H Beijnen,et al.  The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. , 2003, Cancer research.

[9]  K. Locher,et al.  Structure of an ABC transporter in complex with its binding protein , 2007, Nature.

[10]  Xingrong Liu,et al.  Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development. , 2003, Current drug metabolism.

[11]  A. E. Senior,et al.  The catalytic cycle of P‐glycoprotein , 1995, FEBS letters.

[12]  M. Barrand,et al.  Localisation of breast cancer resistance protein in microvessel endothelium of human brain , 2002, Neuroreport.

[13]  Balázs Sarkadi,et al.  The role of ABC transporters in drug resistance, metabolism and toxicity. , 2004, Current drug delivery.

[14]  A. Seelig,et al.  Structure-activity relationship of P-glycoprotein substrates and modifiers. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  Yuichi Sugiyama,et al.  Comparative Studies on in Vitro Methods for Evaluating in Vivo Function of MDR1 P-Glycoprotein , 2001, Pharmaceutical Research.

[16]  U. Hofmann,et al.  Increased Absorption of Digoxin from the Human Jejunum Due to Inhibition of Intestinal Transporter-Mediated Efflux , 2007, Clinical pharmacokinetics.

[17]  J. Schellens,et al.  Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. , 2006, Trends in pharmacological sciences.

[18]  Joseph W. Polli,et al.  Role of P-Glycoprotein on the CNS Disposition of Amprenavir (141W94), an HIV Protease Inhibitor , 1999, Pharmaceutical Research.

[19]  R. Evers,et al.  Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. , 2000, Molecular pharmacology.

[20]  R. Dawson,et al.  Structure and mechanism of ABC transporter proteins. , 2007, Current opinion in structural biology.

[21]  P. Kwan,et al.  Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy , 2005, Epilepsia.

[22]  J. Beijnen,et al.  Multidrug Resistance Proteins 2 and 3 Provide Alternative Routes for Hepatic Excretion of Morphine-Glucuronides , 2007, Molecular Pharmacology.

[23]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[24]  L. Szente,et al.  Cholesterol Potentiates ABCG2 Activity in a Heterologous Expression System: Improved in Vitro Model to Study Function of Human ABCG2 , 2007, Journal of Pharmacology and Experimental Therapeutics.

[25]  H. Koepsell,et al.  The SLC22 drug transporter family , 2004, Pflügers Archiv.

[26]  Christoph Globisch,et al.  Structure-function relationships of multidrug resistance P-glycoprotein. , 2004, Journal of medicinal chemistry.

[27]  R. O. Oude Elferink,et al.  ABC of oral bioavailability: transporters as gatekeepers in the gut , 2003, Gut.

[28]  Joanna Owens,et al.  Chris Lipinski discusses life and chemistry after the Rule of Five. , 2003 .

[29]  C. Dey,et al.  P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. , 2003, Pharmacological research.

[30]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Schellens,et al.  Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. , 2002, The oncologist.

[32]  C. Deber,et al.  Transmembrane aromatic amino acid distribution in P-glycoprotein. A functional role in broad substrate specificity. , 1994, Journal of molecular biology.

[33]  Y. Sugiyama,et al.  Quantitative Evaluation of the Function of Small Intestinal P-Glycoprotein: Comparative Studies Between in Situ and in Vitro , 2003, Pharmaceutical Research.

[34]  J. Schellens,et al.  Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Shiew-Mei Huang,et al.  Scientific perspectives on drug transporters and their role in drug interactions. , 2006, Molecular pharmaceutics.

[36]  Lippincott-Schwartz,et al.  Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page , 2022 .

[37]  W. Stein,et al.  Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. , 1997, Physiological reviews.

[38]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[39]  Paola Vergani,et al.  CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains , 2005, Nature.

[40]  T. Druley,et al.  From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance , 2001, Cellular and Molecular Life Sciences CMLS.

[41]  Yuichi Sugiyama,et al.  ABCG2 Transports Sulfated Conjugates of Steroids and Xenobiotics* , 2003, Journal of Biological Chemistry.

[42]  A. Schinkel,et al.  The physiological function of drug-transporting P-glycoproteins. , 1997, Seminars in cancer biology.

[43]  J. Schellens,et al.  Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. , 1999, Cancer research.

[44]  H. McLeod,et al.  ABCG2 Pharmacogenetics , 2004, Clinical Cancer Research.

[45]  Alfred H. Schinkel,et al.  BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) TRANSPORTS FLUOROQUINOLONE ANTIBIOTICS AND AFFECTS THEIR ORAL AVAILABILITY, PHARMACOKINETICS, AND MILK SECRETION , 2006, Drug Metabolism and Disposition.

[46]  C. Wandel,et al.  Increased drug delivery to the brain by P‐glycoprotein inhibition , 2000, Clinical pharmacology and therapeutics.

[47]  T. Fojo,et al.  Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  R. Brennan,et al.  A structure-based mechanism for drug binding by multidrug transporters. , 2000, Trends in biochemical sciences.

[49]  Elizabeth Fox,et al.  Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor , 2007, Expert review of anticancer therapy.

[50]  B. Sarkadi,et al.  Calcein accumulation as a fluorometric functional assay of the multidrug transporter. , 1994, Biochimica et biophysica acta.

[51]  Peter J. Meier,et al.  Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties , 2004, Pflügers Archiv.

[52]  A. Schinkel,et al.  Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. , 2003, Advanced drug delivery reviews.

[53]  J. Schellens,et al.  Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles , 2004, Cancer Research.

[54]  B. Hirst,et al.  The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[55]  W. L. Chiou,et al.  A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. , 2001, International journal of clinical pharmacology and therapeutics.

[56]  Yuichi Sugiyama,et al.  Role of Breast Cancer Resistance Protein (Bcrp1/Abcg2) in the Extrusion of Glucuronide and Sulfate Conjugates from Enterocytes to Intestinal Lumen , 2005, Molecular Pharmacology.

[57]  L. Benet,et al.  Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. , 2004, International journal of pharmaceutics.

[58]  J. Schuetz,et al.  Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. Wijnholds,et al.  Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. , 2006, Journal of hepatology.

[60]  M. Oshimura,et al.  FUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA , 2005, Drug Metabolism and Disposition.

[61]  H. Rosing,et al.  The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[62]  K. Linton,et al.  Evidence for a Sav1866‐like architecture for the human multidrug transporter P‐glycoprotein , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[63]  B. Sarkadi,et al.  Characterization of Drug Transport, ATP Hydrolysis, and Nucleotide Trapping by the Human ABCG2 Multidrug Transporter , 2002, The Journal of Biological Chemistry.

[64]  Jos H. Beijnen,et al.  Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein , 1997, Nature Medicine.

[65]  In vitro ADME phenotyping in drug discovery: current challenges and future solutions. , 2005, Current opinion in drug discovery & development.

[66]  T. Ishikawa,et al.  The ATP-dependent glutathione S-conjugate export pump. , 1992, Trends in biochemical sciences.

[67]  T. Litman,et al.  Pumping of Drugs by P-Glycoprotein: A Two-Step Process? , 2003, Journal of Pharmacology and Experimental Therapeutics.

[68]  S. H. Lee,et al.  Expression of functional multidrug-resistance protein 1 in Saccharomyces cerevisiae: effects of N- and C-terminal affinity tags. , 2003, Biochemical and biophysical research communications.

[69]  C. B. Roth,et al.  Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters. , 2001, Science.

[70]  J. Verweij,et al.  Role of pharmacogenetics in irinotecan therapy. , 2006, Cancer letters.

[71]  C. Xia,et al.  Evaluation of drug-transporter interactions using in vitro and in vivo models. , 2007, Current drug metabolism.

[72]  Suneet Shukla,et al.  The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. , 2006, Biochemistry.

[73]  Yuichi Sugiyama,et al.  In Vivo Evaluation of P-glycoprotein Function at the Blood-Brain Barrier in Nonhuman Primates Using [11C]Verapamil , 2006, Journal of Pharmacology and Experimental Therapeutics.

[74]  S. Cole,et al.  Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. , 2006, Physiological reviews.

[75]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[76]  E. L. Volk,et al.  Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. , 2003, Cancer research.

[77]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[78]  M. J. van de Vijver,et al.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.

[79]  R. Dawson,et al.  Structure of a bacterial multidrug ABC transporter , 2006, Nature.

[80]  T. Litman,et al.  Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. , 2001, Biochemical and biophysical research communications.

[81]  I. Pastan,et al.  Heterologous expression systems for P-glycoprotein:E. coli, yeast, and baculovirus , 1995, Journal of bioenergetics and biomembranes.

[82]  J. Hochman,et al.  In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. , 2001, The Journal of pharmacology and experimental therapeutics.

[83]  M. Yamazaki,et al.  Clinical Relevance of P-Glycoprotein in Drug Therapy , 2003, Drug metabolism reviews.

[84]  P. Gros,et al.  Overexpression, purification, and functional characterization of ATP-binding cassette transporters in the yeast, Pichia pastoris. , 2003, Biochimica et biophysica acta.

[85]  K. Miyamoto,et al.  P-Glycoprotein-Dependent Disposition Kinetics of Tacrolimus: Studies in mdr la Knockout Mice , 1999, Pharmaceutical Research.

[86]  H. Kusuhara,et al.  Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: importance in the drug delivery to the brain. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[87]  Y. Sugimoto,et al.  Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug Resistance , 2004, Cancer Research.

[88]  B. Sarkadi,et al.  ABCG2 – a transporter for all seasons , 2004, FEBS letters.

[89]  T. Janvilisri,et al.  Sterol Transport by the Human Breast Cancer Resistance Protein (ABCG2) Expressed in Lactococcus lactis* , 2003, Journal of Biological Chemistry.

[90]  G. Chang,et al.  Structure of the ABC Transporter MsbA in Complex with ADP·Vanadate and Lipopolysaccharide , 2005, Science.

[91]  R. Evers,et al.  Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. , 1996, The Journal of clinical investigation.

[92]  L. Szente,et al.  Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. , 2007, Biochimica et biophysica acta.

[93]  Takashi Tsuruo,et al.  Breast cancer resistance protein exports sulfated estrogens but not free estrogens. , 2003, Molecular pharmacology.

[94]  H. Endou,et al.  The multispecific organic anion transporter family: properties and pharmacological significance. , 2004, Trends in pharmacological sciences.

[95]  D. Clarke,et al.  Substrate-induced Conformational Changes in the Transmembrane Segments of Human P-glycoprotein , 2003, The Journal of Biological Chemistry.

[96]  Geoffrey Chang,et al.  Structure of MsbA from Vibrio cholera: a multidrug resistance ABC transporter homolog in a closed conformation. , 2003, Journal of molecular biology.

[97]  S. Cole,et al.  Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. , 2005, Toxicology and applied pharmacology.

[98]  D. H. Sweet.  Organic anion transporter (Slc22a) family members as mediators of toxicity. , 2005, Toxicology and applied pharmacology.

[99]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[100]  S. Cole,et al.  Substrate recognition and transport by multidrug resistance protein 1 (ABCC1) , 2006, FEBS letters.

[101]  T. Dale,et al.  The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk , 2005, Nature Medicine.

[102]  B. Sarkadi,et al.  Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.